ClinicalTrials.gg
RecruitingNCT07191119Updated Aug 14, 2026

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

An interventional study of Soterix tVNS device and Soterix tVNS device (sham programmed) in Survivor of Childhood Cancer, Insomnia and Acute Lymphoblastic Leukemia (ALL), sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Planned enrollment
536th of 858
40 · median 60
Started
2026
with 60 others
No phase
580 of 907
110 open now
Primary completion
2027-12
later than 124 of 185 live
Registered
828th of 907
by date

Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 536th largest by planned enrollment of the 858 interventional ones that give a count, is one of 61 that started in 2026, is one of 580 with no phase, reaches primary completion later than 124 of the 185 other live ones, and was the 828th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

This pilot study will assess the usefulness and potential effectiveness of using transcutaneous auricular vagus nerve stimulation (tVNS) for treating insomnia in adult survivors of childhood acute lymphoblastic leukemia (ALL). Participants will be randomized to receive either active (verum) or inactive (sham) nightly stimulation using a non-invasive earbud device over two time periods: 2 weeks and 8 weeks. The study will assess adherence to the intervention and estimate its effects on sleep quality, stress, and neurocognitive function.

Primary Objective:

Aim 1: To determine a) short-term and b) long-term feasibility of tVNS in terms of participation in ALL Survivors with moderate to severe insomnia.

Aim 2: To estimate the effect size of tVNS on sleep quality, stress, and neurocognitive outcomes in ALL survivors with insomnia.

Exploratory Objectives

Aim 1: To investigate the onset of tVNS effect via actigraphy measures over the intervention epoch.

Aim 2: To estimate the effect size of genetic variants on sleep quality within verum tVNS.

Read the detailed description

Approximately 40 adult survivors of childhood ALL enrolled in the SJLIFE cohort will be recruited. Eligible participants must have moderate to severe insomnia (ISI ≥8). The intervention involves nightly use of a tVNS device for 20 minutes before sleep. Participants will be randomized to receive either active or sham stimulation. Feasibility will be assessed based on adherence rates, and efficacy will be estimated using subjective (PSQI, ISI) and objective (actigraphy, CNS Vital Signs) measures. Exploratory analyses will examine the onset of tVNS effects and the influence of genetic variants (BDNF rs6265, COMT rs4680) on treatment response.

03

Conditions studied

  • Survivor of Childhood Cancer
  • Insomnia
  • Acute Lymphoblastic Leukemia (ALL)
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Survivor of Acute Lymphoblastic Leukemia (ALL)
  • Enrolled on SJLIFE
  • Participant was less than 21 years of age at time of diagnosis.
  • Age 20-50 years at the time of enrollment
  • Insomnia Severity Index >=8 (Proxy >=8) confirmed prior to enrollment
  • Access to home Wi-Fi and Smartphone
  • Participant is able to speak and understand the English language
  • Participant is able and willing to give consent

Exclusion criteria

Exclusion Criteria:

  • Unable to understand the details and requirements of the study (at the discretion of the PI)
  • Female participants who are pregnant or planning to become pregnant
  • Presence of implanted electrical medical devices (i.e. pacemaker)
  • Currently taking medication intended to treat neurocognitive impairment (i.e. stimulants) or medications prescribed for seizure management
  • History of skin irritation or other issues during stimulation of inner ear
  • Currently utilizing a technological intervention for a sleep disorder (e.g. CPAP)
  • Medications and behavioral practices (white noise, night-time yoga, etc) are acceptable as long as the insomnia is persistent.
  • History of a health condition including:
  • Syncope ( >2)
  • Cardiac dysrhythmia (CTCAE >2)
  • Vascular Disease (CTCAE >2)
  • Coronary Artery Disease (CTCAE >2)
  • Active contraindicated heath condition including:
  • Cranial Nerve Disorder (CTCAE >2)
  • Cardiac tachycardia (CTCAE >2)
  • Neuropathy (Cranial Nerves) (CTCAE >2)
  • Neuralgia (Cranial Nerves) (CTCAE >2)
  • Overt Cerebrovascular Accident (CTCAE >2)
  • Seizures (Any in most recent 1 year
  • Currently enrolled or participating in any other neurostimulation or neuromodulation ancillary research studies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Verum tVNS (Active Treatment)

    Participants randomized to receive active transcutaneous auricular vagus nerve stimulation (tVNS) using the Soterix device. Stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold.

    Device: Soterix tVNS device · Behavioral: Sleep Quality · Behavioral: Neurocognitive and mental health outcomes

  • Sham comparator
    Sham tVNS (Placebo Comparator)

    Participants randomized to receive sham stimulation using the same Soterix device, but with no active electrical stimulation. The procedure mimics the verum condition in duration and setup.

    Device: Soterix tVNS device (sham programmed) · Behavioral: Sleep Quality · Behavioral: Neurocognitive and mental health outcomes

Interventions

  • DeviceSoterix tVNS device

    Active transcutaneous auricular vagus nerve stimulation (tVNS) using the Soterix device. Stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold.

    Also known as: tVNS

  • DeviceSoterix tVNS device (sham programmed)

    The sham stimulation used the Soterix device, but without active electrical stimulation. The procedure mimics the verum condition in duration and setup. Inactive stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold.

  • BehavioralSleep Quality

    Receive Pittsburgh Sleep Quality Index (PSQI); Insomnia Severity Index (ISI); Sleep diaries; Actigraphy via Fitbit Charge 5

  • BehavioralNeurocognitive and mental health outcomes

    Measured using CNS Vital Signs and DASS-21.

06

What researchers measure

Primary outcomes

  1. Mean Change in Subjective Sleep Quality

    Pittsburgh Sleep Quality Index (PSQI, 0-57 points). Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-weeks, 8-weeks

  2. Mean change in clinical insomnia score

    Insomnia Severity Index (ISI, 0-28 points). Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-weeks, 8-weeks

  3. Occurrence of side effects

    Patient Report of Incidence of Side Effects (PRISE). Descriptive statistics of the change between baseline and 2 and 8 weeks will be reported.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7

  4. Adherence to intervention

    Number of tVNS sessions performed. Descriptive statistics of adherence at 2 weeks and 8 weeks will be reported.

    Time frame: 2-weeks, 8-weeks

  5. Mean change in Processing Speed (age adjusted z-score)

    Symbol Digit Coding Test as the difference between correct responses and errors. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  6. Mean change in Executive Function (age adjusted z-score)

    Shifting Attention Task as the difference between correct responses and errors. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  7. Mean change in Simple Attention (age adjusted z-score)

    Continuous Performance Test as the difference between correct responses and commission errors. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  8. Mean change in Reaction Time (age adjusted z-score)

    Stroop Test as the average of reaction times in the complex and default trials. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  9. Mean change in Sustained Attention (age adjusted z-score)

    Four-Part Continuous Performance Test as the difference between correct responses and incorrect responses in Part 2, 3, and 4. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  10. Mean change in Working Memory (age adjusted z-score)

    Four-Part Continuous Performance Test as the difference between correct responses and incorrect responses in Part 4 only. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  11. Mean change in Complex Attention (age adjusted z-score)

    Evaluated with the Stroop Test (ST), Shifting Attention Test (SAT), and Continuous Performance Test (CPT) as the sum of ST commission errors, SAT errors, CPT commission errors, and CPT omission errors. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  12. Mean change in Cognitive Flexibility (age adjusted z-score)

    Evaluated with the Stroop Test (ST) and Shifting Attention Test (SAT) as the difference between SAT correct responses and the sum of the SAT errors and ST commission errors. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Baseline, 2-Weeks, 8-weeks

  13. Mean change in Depression, Anxiety, and Stress (scales)

    Evaluated with Depression Anxiety Stress Scale Short Form (DASS SF-21). Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported. DASS SF-21 are reported as population z-scores and categorized into five severity ranges: normal, mild, moderately severe, and extremely severe. The severity levels, higher percentiles being more severe, are determined by z-scores from the DASS manual.

    Time frame: Baseline, 2-Weeks, 8-weeks

  14. Mean Change in Heart Rate Variability (ms)

    Root Mean Square Successive Difference (RMSSD) of heart rate variability. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Weekly means of daily measurements at baseline, at 2-weeks, and at 8-weeks

  15. Mean Change in Sleep Onset Latency (minutes)

    Sleep Onset Latency (time in bed before sleep). Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Weekly means of daily measurements at baseline, at 2-weeks, and at 8-weeks

  16. Mean Change in Waking Events (count)

    Number of Awakenings. Descriptive statistics of the difference between experiment arms of the change between baseline and 2 weeks, and baseline and 8 weeks will be reported.

    Time frame: Weekly means of daily measurements at baseline, at 2-weeks, and at 8-weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of article publication.

Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 24, 2025
StartActual
Mar 31, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2029
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07191119
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Mar 31, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Aug 14, 2026

Study contacts

Justin E Tanner, PhD
Contact
referralinfo@stjude.org
888-226-4343
Justin E Tanner, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion